Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 43Prostatic Neoplasms, Castration-Resistant 6Neoplasm Metastasis 5Metastatic Castration-resistant Prostate Cancer 4Breast Neoplasms 4Prostate Carcinoma Metastatic to the Bone 2Neoplasms 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Hormone Refractory Prostate Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bone Metastatic Castration-resistant Prostate Cancer 2Thyroid Neoplasms 1Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Pain 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Lung Neoplasms 1Fractures, Bone 1Fatigue 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Bony Metastases From Castrate Refractory Prostate Cancer 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Prednisone 2Docetaxel 2radium Ra 223 dichloride 1cabazitaxel 1atezolizumab 1Sodium Chloride 1OGX-011 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castrate-Resistant Prostate Cancer × radium Ra 223 dichloride × Clear all
NCT02814669 2019-09-24

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Hoffmann-La Roche

Phase 1 Completed
45 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡